8-K: Dynavax Reports Record HEPLISAV-B Revenue and Advances Pipeline in Q2 2024

Dynavax Technologies Corporation announced record quarterly revenue for its HEPLISAV-B vaccine and provided updates on its clinical pipeline, including the initiation of a Phase 1/2 trial for a novel shingles vaccine.

Summary

• Dynavax reported a strong second quarter in 2024, with total revenues reaching $73.8 million, a 22% increase year-over-year.
• HEPLISAV-B net product revenue hit a record $70.2 million, a 24% increase compared to the same quarter last year.
• The company's market share for HEPLISAV-B in the U.S. increased to approximately 42%, with even higher shares in retail pharmacies (59%) and Integrated Delivery Networks (56%).
• Dynavax reaffirmed its full-year 2024 HEPLISAV-B net product revenue guidance of $265 $280 million.
• A Phase 1/2 trial for a novel shingles vaccine program was initiated, with clinical data expected in the second half of 2025.
• The company expects the HEPLISAV-B market opportunity to grow to over $800 million by 2027 and continue expanding through the end of the decade.
• Net income for the quarter was $11.4 million, or $0.09 per share basic and $0.08 diluted, compared to $3.4 million, or $0.03 per share in the second quarter of 2023.
• Cash and marketable securities totaled $735.6 million as of June 30, 2024.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to record revenue, increased market share, and pipeline advancements. The company's strong financial position and positive outlook contribute to the high score. The FDA CRL is a minor negative but is being addressed.

Positives

• The company achieved record quarterly revenue for HEPLISAV-B, demonstrating strong market demand.
• HEPLISAV-B market share is increasing across all key segments, including retail pharmacies and Integrated Delivery Networks.
• The initiation of the Phase 1/2 trial for the shingles vaccine program marks a significant step in pipeline development.
• The company is maintaining a strong financial position with over $735 million in cash and marketable securities.
• Net income significantly improved compared to the same quarter last year.
• Cost of sales for HEPLISAV-B decreased due to lower per-unit manufacturing costs.

Negatives

• The FDA issued a Complete Response Letter (CRL) for the supplemental Biologics License Application (sBLA) for a four-dose HEPLISAV-B regimen for adults on hemodialysis.
• Other revenue decreased by 5% compared to the second quarter of 2023.
• Research and development expenses increased to $15.0 million, driven by investments in the pipeline.
• Selling, general, and administrative expenses increased to $41.7 million due to increased headcount and strategic growth investments.

Risks

• The company faces the risk that actual demand for its products may differ from expectations.
• There are risks related to the company's ability to commercialize and supply HEPLISAV-B.
• The timing of completion and results of current clinical studies are subject to risks.
• The development and testing of vaccines containing CpG 1018 adjuvant carry inherent risks.
• The company needs to address the FDA's Complete Response Letter for the hemodialysis sBLA.

Future Outlook

Dynavax is reaffirming its full-year 2024 financial guidance, expecting HEPLISAV-B net product revenue between $265 $280 million, a gross margin of approximately 80%, R&D expenses between $60 $75 million, and SG&A expenses between $160 $180 million. The company also expects cash, cash equivalents and marketable securities to be higher as of December 31, 2024, compared to December 31, 2023.

Management Comments

• We continue to strengthen our leadership position in the U.S. adult hepatitis B vaccine market with another record quarter for HEPLISAV-B, providing confidence in our current year expectations and reaffirming our long-term view of the product opportunity, said Ryan Spencer, Chief Executive Officer of Dynavax.
• We are highly optimistic about the adult hepatitis B vaccine market of over 130 million eligible patients, which is one of the largest addressable patient populations for vaccines in the U.S.
• The expected growth in the market opportunity, combined with our expectations to continue to increase market share, provides a substantial, long-term revenue opportunity for HEPLISAV-B.

Industry Context

The announcement highlights Dynavax's strong position in the adult hepatitis B vaccine market, which is a large and growing market. The company's focus on expanding its pipeline with a shingles vaccine and other programs aligns with the industry trend of developing innovative vaccines for infectious diseases. The company's success with HEPLISAV-B also positions it well to leverage its CpG 1018 adjuvant in other vaccine programs.

Comparison to Industry Standards

• Dynavax's HEPLISAV-B is a two-dose vaccine, which is a competitive advantage compared to older three-dose hepatitis B vaccines, such as those from GSK (Engerix-B) and Merck (Recombivax HB).
• The company's 42% market share in the U.S. for HEPLISAV-B is a significant achievement, indicating strong adoption by healthcare providers and patients.
• The projected market opportunity of over $800 million by 2027 for HEPLISAV-B is substantial, suggesting a strong growth trajectory compared to other vaccines in the market.
• The initiation of a Phase 1/2 trial for a shingles vaccine puts Dynavax in competition with established players like GSK (Shingrix), but the company's novel approach with CpG 1018 adjuvant could offer a differentiated product.

Stakeholder Impact

• Shareholders will likely view the record revenue and increased market share positively.
• Employees may benefit from the company's growth and strategic investments.
• Customers (healthcare providers and patients) will have increased access to HEPLISAV-B and potentially new vaccines in the future.
• Suppliers may see increased demand for their products and services.
• Creditors will likely view the company's strong financial position favorably.

Next Steps

• Dynavax intends to meet with the FDA in the second half of 2024 to discuss pathways to amend its sBLA for the four-dose HEPLISAV-B regimen for adults on hemodialysis.
• The company anticipates reporting top line immunogenicity and safety data from the shingles vaccine trial in the second half of 2025.
• Results from the Phase 1 extension study of the Tdap vaccine program and a program update on the plague vaccine program are expected in the fourth quarter of 2024.

Key Dates

Keywords

HEPLISAV-B, Hepatitis B vaccine, Shingles vaccine, Vaccine, Dynavax, CpG 1018 adjuvant, Clinical trial, Biopharmaceutical, Revenue, Market share